Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxid...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Zhang, Hongyu, Saha, Jharna, Byun, Jaeman, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, Brosius, Frank C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Physiological Society 2008
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2576144/
https://ncbi.nlm.nih.gov/pubmed/18667486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.90208.2008
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia